» Articles » PMID: 24778448

Ikaros Imposes a Barrier to CD8+ T Cell Differentiation by Restricting Autocrine IL-2 Production

Overview
Journal J Immunol
Date 2014 Apr 30
PMID 24778448
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Naive CD4(+) T cells require signals from the TCR and CD28 to produce IL-2, expand, and differentiate. However, these same signals are not sufficient to induce autocrine IL-2 production by naive CD8(+) T cells, which require cytokines provided by other cell types to drive their differentiation. The basis for failed autocrine IL-2 production by activated CD8(+) cells is unclear. We find that Ikaros, a transcriptional repressor that silences IL-2 in anergic CD4(+) T cells, also restricts autocrine IL-2 production by CD8(+) T cells. We find that CD8(+) T cell activation in vitro in the absence of exogenous cytokines and CD4 help leads to marked induction of Ikaros, a known repressor of the Il2 gene. Naive murine CD8 T cells haplo-insufficient for Ikzf1 failed to upregulate Ikaros, produced autocrine IL-2, and differentiated in an IL-2-dependent manner into IFN-γ-producing CTLs in response to TCR/CD28 stimulation alone. Furthermore, Ikzf1 haplo-insufficient CD8(+) T cells were more effective at controlling Listeria infection and B16 melanoma growth in vivo, and they could provide help to neighboring, non-IL-2-producing cells to differentiate into IFN-γ-producing effectors. Therefore, by repressing autocrine IL-2 production, Ikaros ensures that naive CD8(+) T cells remain dependent on licensing by APCs and CD4(+) T cells, and it may therefore act as a cell-intrinsic safeguard against inappropriate CTL differentiation and immunopathology.

Citing Articles

Degradation of IKZF1 prevents epigenetic progression of T cell exhaustion in an antigen-specific assay.

Tay T, Bommakanti G, Jaensch E, Gorthi A, Karapa Reddy I, Hu Y Cell Rep Med. 2024; 5(11):101804.

PMID: 39486420 PMC: 11604474. DOI: 10.1016/j.xcrm.2024.101804.


LIM-domain-only 4 (LMO4) enhances CD8 T-cell stemness and tumor rejection by boosting IL-21-STAT3 signaling.

Schelker R, Fioravanti J, Mastrogiovanni F, Baldwin J, Rana N, Li P Signal Transduct Target Ther. 2024; 9(1):199.

PMID: 39117617 PMC: 11310520. DOI: 10.1038/s41392-024-01915-z.


Foxp3 depends on Ikaros for control of regulatory T cell gene expression and function.

Thomas R, Pahl M, Wang L, Grant S, Hancock W, Wells A Elife. 2024; 12.

PMID: 38655862 PMC: 11042806. DOI: 10.7554/eLife.91392.


TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells.

Cianciotti B, Magnani Z, Ugolini A, Camisa B, Merelli I, Vavassori V Front Immunol. 2024; 15:1315283.

PMID: 38510235 PMC: 10953820. DOI: 10.3389/fimmu.2024.1315283.


Role of tumor-associated neutrophils in lung cancer (Review).

Zhou J, Liu H, Jiang S, Wang W Oncol Lett. 2022; 25(1):2.

PMID: 36419755 PMC: 9677518. DOI: 10.3892/ol.2022.13588.


References
1.
Bos R, Sherman L . CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 2010; 70(21):8368-77. PMC: 2970736. DOI: 10.1158/0008-5472.CAN-10-1322. View

2.
Malek T . The biology of interleukin-2. Annu Rev Immunol. 2007; 26:453-79. DOI: 10.1146/annurev.immunol.26.021607.090357. View

3.
Cruz-Guilloty F, Pipkin M, Djuretic I, Levanon D, Lotem J, Lichtenheld M . Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. J Exp Med. 2009; 206(1):51-9. PMC: 2626671. DOI: 10.1084/jem.20081242. View

4.
Avitahl N, Winandy S, Friedrich C, Jones B, Ge Y, Georgopoulos K . Ikaros sets thresholds for T cell activation and regulates chromosome propagation. Immunity. 1999; 10(3):333-43. DOI: 10.1016/s1074-7613(00)80033-3. View

5.
Williams M, Tyznik A, Bevan M . Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature. 2006; 441(7095):890-3. PMC: 2776073. DOI: 10.1038/nature04790. View